Joshua Jackson is counsel in the technology and intellectual property practice groups and has 15+ years of experience advising technology and biotechnology companies with respect to intellectual property and strategic transactional matters. With a background in electrical engineering, computer science and biomedical engineering, Josh advises public and private companies, investors, and universities in a variety of transactions where technology, data or IP assets are the fundamental drivers. These transactions include intellectual property licensing and transfer, product development and research collaborations, joint ventures, technology-focused mergers and acquisitions, cloud contracts, branding, supply agreements, copyright and trademark matters, venture financings and other strategic relationships. Josh works with companies in a broad range of industries including fintech, digital health, biotechnology, artificial intelligence, semiconductor, cloud-computing, software, pharmaceutical, medical device, and media and entertainment industries. Josh also advises companies in connection with use of artificial intelligence and machine learning technology, as well as digital asset custody and transactional matters that focus on blockchain, non-fungible tokens (NFTs) and cryptocurrency.
In addition to his transactional experience, Josh has extensive experience assisting clients ranging from small start-up companies to large domestic and international corporations with preparing and prosecuting patent applications, strategically developing and managing patent portfolios, forming IP ownership and monetization strategies, and conducting patent infringement, validity and freedom to operate analyses for a wide range of technologies.
Prior to joining the firm, Josh's biomedical engineering graduate work at the University of Michigan focused on research topics in the area of implantable MEMS neural probes and in exploiting the near-infrared absorbance properties of carbon nanotubes for destroying cancerous cells. Josh has also worked at Cleveland Clinic where he researched the effects of Deep Brain Stimulation on Parkinson's disease.
Experience
- Advised Bain Capital in numerous transactions, including:
- in a definitive agreement valued at up to $4.5 billion, to acquire Envestnet, a leading provider of integrated technology, intelligent data and wealth solutions;
- its acquisition of PowerSchool Holdings, Inc, a leading provider of cloud-based software for K-12 education. The transaction values the PowerSchool at $5.6 billion;
- its $900 million acquisition of Extrahop, a leader in cloud-native cybersecurity, network detection and response.
- Advised private equity firm AEA Investors and its portfolio company Process Sensing Technologies (PST) in PST’s acquisition of Fluid Components International (FCI).
- Advises multiple asset management companies on issues around the acquisition and management of artificial intelligence, data and other technology systems for use in algorithmic and quantitative trading, and the technologies associated with executing their strategies.
- Represented Morgan Stanley Tactical Value in its partnership with Kobalt Partners to invest more than $700 million to acquire music copyrights over the next few years.
- Represents a leading global investment banking firm in a number of high-profile, financial services technology transactions related to data distribution, index-licensing, data use, and licensing of technology directed toward trading platforms, including providing strategic guidance for licensing and patent strategy.
- Represented TPG Growth in connection with its acquisition of Musixmatch, a music lyrics tech and data company based in Italy. Musixmatch features the world’s largest lyrics metadata collection, which it provides to digital service providers including Amazon Music, Apple Music, Google, Instagram, Spotify, and Tidal.
- Represented TPG Capital in numerous transactions including:
- its acquisition of Wind River Systems, Inc., a world leader in embedded software for intelligent connected systems, from Intel Corporation; and
- its $4 billion divestiture of McAfee’s enterprise assets to Symphony Technology Group in a complex carve-out deal.
- Represented Invesco in numerous transactions, including:
- its migration to, and integration of, State Street’s Alpha platform, a front-to-back asset servicing platform for institutional and wealth management firms; and
- its strategic acquisitions of various companies with robo advisor and asset rebalancing technologies.
- Represented McAfee Corp. in connection with its acquisition by an investor group comprised of Advent, Permira, Crosspoint Capital, CPP Investments, GIC and ADIA for over $14 billion.
- Represented American Industrial Partners in its growth investment in Trew Automation, a provider of automated material handling solutions for the distribution and fulfillment industry.
- Represented Virtusa Corporation, a global provider of digital strategy, digital engineering, and information technology (IT) services, in its acquisition of Factor Creative LLC, a prominent full-service creative agency.
- Represented HP Inc. in its acquisition of Teradici Corporation, a global innovator in remote computing software.
- Represented Astra, a rocket launch startup that provides satellite delivery service, in its US$2.1 billion business combination with Holicity, a special purpose acquisition company (SPAC).
- Represented Qorvo, a leading semiconductor company, and Qorvo Biotechnologies, with respect to a development and supply agreement with Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, to collaborate on the development of veterinary diagnostic assays with the goal of delivering reference-lab performance at the point of care.
- Represented a global music entertainment company in negotiating multiple commercial agreements with major artificial intelligence technology providers.
- Represented a technology company in connection with a complex cross-license required under a settlement agreement.
- Represented MACOM Technology Solutions, a leading supplier of high-performance RF, microwave, millimeterwave, and lightwave semiconductor products, in its acquisition of Applied Micro Circuits Corporation.
- Represented Flight Centre Travel Group in its investment in, and collaboration with, The Upside Travel Company to integrate its cutting edge artificial intelligence and machine learning technology platform and software.
- Represented Genesis Therapeutics, a Stanford University spin-out company with a focus on artificial intelligence, in multiple transactions focusing on using Genesis’s AI-driven drug discovery platform to identify new drug candidates that target and treat severe diseases, including:
- a multi-target collaboration with Gilead, with payments to Genesis up to $35 million to leverage its GEMS AI Platform to generate and jointly optimize molecules against selected targets;
- a multi-target collaboration with Genentech, a member of the Roche Group; and
- a five-target collaboration with Eli Lilly and Company, with payments to Genesis up to $670 million.
- Represented a global biotechnology company in its strategic research and collaboration agreement with a pharmaceutical and biotechnology company to discover and develop potential new treatments.
- Represented Homology Medicines in its research and development collaboration with Novartis to use Homology's gene editing technology to develop new treatments for select ophthalmic targets and hemoglobin blood disease.
- Represented ImmunoGen in its collaboration and option agreement with Jazz Pharmaceuticals, granting Jazz exclusive, worldwide rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate programs, as well as an additional program to be designated during the term of the agreement. Jazz paid $75 million upfront and committed to pay $100 million in development funding plus milestones and royalties.
- Represented a major U.S. health system in a joint venture establishing a data innovation company utilizing AI for the analysis of health data.
- Represented Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, in a five-year strategic cloud and AI partnership with Google Cloud, intended to enable Ginkgo to develop and deploy AI tools for biology and biosecurity.
- Represented a multinational pharmaceutical, biotechnology, and medical technologies corporation in numerous transactions, including:
- in its collaboration with an AI-driven antibody discovery platform to guide the design and selection for high-quality antibodies for multiple neuroscience therapeutic targets; and
- in its development and distribution agreement with a medical technology company, to integrate customized technology into its product for hip replacement surgery.